Esperion Therapeutics, Inc. (ESPR)
Jul 13, 2026 - ESPR was delisted
3.180
-0.010 (-0.31%)
Inactive · Last trade price on Jul 10, 2026
Esperion Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 418.24 | 403.14 | 332.31 | 116.33 | 75.48 | 78.45 | |
Revenue Growth | 61.13% | 21.31% | 185.66% | 54.14% | -3.79% | -65.53% |
Cost of Revenue | 176.54 | 177.08 | 114.84 | 129.37 | 145.89 | 120.19 |
Gross Profit | 241.7 | 226.06 | 217.48 | -13.04 | -70.42 | -41.75 |
Selling, General & Admin | 165.91 | 165.79 | 163.07 | 142.52 | 109.08 | 171.74 |
Operating Expenses | 165.91 | 165.79 | 163.07 | 142.52 | 109.08 | 171.74 |
Operating Income | 75.79 | 60.27 | 54.4 | -155.56 | -179.5 | -213.48 |
Interest Expense | -84.97 | -84.6 | -59.25 | -58.98 | -56.81 | -46.35 |
Interest & Investment Income | 3.6 | 3.5 | 7.6 | 4.4 | 2.4 | 0.1 |
Other Non Operating Income (Expenses) | 0 | -0.01 | 0.42 | 0.48 | 0.53 | 1.24 |
EBT Excluding Unusual Items | -5.58 | -20.84 | 3.17 | -209.66 | -233.38 | -258.49 |
Gain (Loss) on Sale of Investments | - | - | - | 0.41 | -0.28 | -0.01 |
Legal Settlements | - | - | - | - | - | -18.25 |
Other Unusual Items | - | - | -54.92 | - | - | 2.65 |
Pretax Income | -5.58 | -20.84 | -51.75 | -209.25 | -233.66 | -269.11 |
Income Tax Expense | 1.84 | 1.84 | - | - | - | - |
Net Income | -7.42 | -22.68 | -51.75 | -209.25 | -233.66 | -269.11 |
Net Income to Common | -7.42 | -22.68 | -51.75 | -209.25 | -233.66 | -269.11 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 222 | 208 | 187 | 103 | 66 | 29 |
Shares Outstanding (Diluted) | 222 | 208 | 187 | 103 | 66 | 29 |
Shares Change | 14.32% | 11.05% | 81.54% | 55.26% | 129.76% | 5.20% |
EPS (Basic) | -0.03 | -0.11 | -0.28 | -2.03 | -3.52 | -9.31 |
EPS (Diluted) | -0.03 | -0.11 | -0.28 | -2.03 | -3.52 | -9.31 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -18.38 | -13.09 | -23.97 | -135.49 | -174.83 | -263.81 |
Free Cash Flow Per Share | -0.08 | -0.06 | -0.13 | -1.31 | -2.63 | -9.13 |
Gross Margin | 57.79% | 56.07% | 65.44% | -11.21% | -93.30% | -53.21% |
Operating Margin | 18.12% | 14.95% | 16.37% | -133.72% | -237.83% | -272.13% |
Profit Margin | -1.77% | -5.63% | -15.57% | -179.87% | -309.58% | -343.04% |
Free Cash Flow Margin | -4.39% | -3.25% | -7.21% | -116.46% | -231.64% | -336.29% |
EBITDA | 75.89 | 60.38 | 54.47 | -155.4 | -179 | -212.87 |
EBITDA Margin | 18.15% | 14.98% | 16.39% | -133.58% | -237.17% | -271.35% |
D&A For EBITDA | 0.11 | 0.11 | 0.06 | 0.16 | 0.5 | 0.61 |
EBIT | 75.79 | 60.27 | 54.4 | -155.56 | -179.5 | -213.48 |
EBIT Margin | 18.12% | 14.95% | 16.37% | -133.72% | -237.83% | -272.13% |
Revenue as Reported | 418.24 | 403.14 | 332.31 | 116.33 | 75.48 | 78.45 |
Advertising Expenses | - | 25 | 25.5 | 15.6 | 11.3 | 13.7 |